Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Composite Interceptive Med Science
- Trial code
- NCT03503708
- Record updated
- 20 April 2018
- Original description
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.Read full original descriptionShow less
Antioxidant for Improvement of Hepatic Function in Patients With Alcohol Liver Disease Without Cirrhosis: Non-randomized Interventional Cohort Study
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.
Inclusion: Adults aged over 18 years with the evidence of alcoholic liver disease (ALD) based on a thorough history, physical examination, and laboratory tests and all of the following:; Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire; Active alcohol use until 4 weeks prior to presentation; ALT and AST elevated >1.5 times the upper limit of normal; Over 1.5 ratio of AST to ALT; Maddrey Discriminant function(DF) less than 30.
Exclusion: Participants on hepatotoxic medications like antitubercular medication, antiviral medication, paracetamol etc; Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days; Severe alcoholic hepatitis with cirrhosis or life expectancy less than 3 months; Severe renal impairment (Glomerular filtration rate below 60 ml/min per 1.73m2); Hepatic disorders due to cardiac causes, inherited metabolic causes, hemochromatosis and Wilson's disease; Participants with active viral hepatitis; Under going active treatment for alcohol withdrawal syndrome(AWS) at the study entry; Pregnant, attempting to conceive, or lactating women.